Association of High Mobility Group Box-Protein 1 and Platelet Microparticles in Patients After Hematopoietic Stem Cell Transplantation

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 11

PMID 37563884

Authors

Shosaku Nomura

Jun Ichikawa

Toshiki Shimizu

Yoshihisa Ishiura

Masaya Okada

Kazuyoshi Ishii

Tomoki Ito

Affiliations

Soon will be listed here.

Abstract

Thrombotic complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly impact transplant outcomes. We focused on high mobility group box-protein (HMGB)1, one causative agent of thrombotic lesions in allo-HSCT, and investigated its association with platelets. We statistically analyzed available data from 172 patients with hematopoietic malignancies receiving allo-HSCT. A significant enhancement of monocyte-chemotactant protein-1, HMGB1, and platelet-derived microparticle (PDMP) levels was observed at day 0 after transplantation as compared to pre-transplantation. Multivariate analysis of the association among HMGB1 and 16 factors on day 0 revealed a significant correlation of HMGB1 levels with thrombin-antithrombin complex, interleukin-6, and PDMPs. High mobility group box-protein 1-induced procoagulant platelet induction and PDMP generation were performed in vitro using healthy platelets. High mobility group box-protein 1-induced PDMP generation was suppressed by toll-like receptor inhibitors and recombinant thrombomodulin. These results suggest that HMGB1 contributes to platelet activation in patients after allo-HSCT and is associated with PDMP-related thrombotic complications.

Citing Articles

Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus.

Nomura S, Taniura T, Ichikawa J, Iwama A, Ito T Clin Appl Thromb Hemost. 2024; 30:10760296241302082.

PMID: 39587795 PMC: 11590140. DOI: 10.1177/10760296241302082.

References

Nomura S, Ito T, Katayama Y, Ota S, Hayashi K, Fujita S . Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation. Transpl Immunol. 2018; 53:28-33. DOI: 10.1016/j.trim.2018.12.001. View

Xu Z, Luo C, Lai P, Ling W, Wu S, Huang X . von Willebrand Factor as a Predictor for Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost. 2020; 26:1076029619892684. PMC: 7256332. DOI: 10.1177/1076029619892684. View

Siess W . Molecular mechanisms of platelet activation. Physiol Rev. 1989; 69(1):58-178. DOI: 10.1152/physrev.1989.69.1.58. View

Yujiri T, Tagami K, Tanaka Y, Mitani N, Nakamura Y, Ariyoshi K . Increased serum levels of high-mobility group box 1 protein in patients who developed acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2010; 85(4):366-7. DOI: 10.1111/j.1600-0609.2010.01507.x. View

Stoffel N, Rysler C, Buser A, Gratwohl A, Tsakiris D, Stern M . Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost. 2010; 103(6):1228-32. DOI: 10.1160/TH09-10-0700. View

Rouhiainen A, Imai S, Rauvala H, Parkkinen J . Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2001; 84(6):1087-94. View

Nomura S . Microparticle and Atherothrombotic Diseases. J Atheroscler Thromb. 2015; 23(1):1-9. DOI: 10.5551/jat.32326. View

Gao Y, Li X, Qin Y, Men J, Ren J, Li X . MPs-ACT, an Assay to Evaluate the Procoagulant Activity of Microparticles. Clin Appl Thromb Hemost. 2023; 29:10760296231159374. PMC: 9972054. DOI: 10.1177/10760296231159374. View

Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L . HMGB1 in health and disease. Mol Aspects Med. 2014; 40:1-116. PMC: 4254084. DOI: 10.1016/j.mam.2014.05.001. View

10.

Nomura S, Ozaki Y, Ikeda Y . Function and role of microparticles in various clinical settings. Thromb Res. 2008; 123(1):8-23. DOI: 10.1016/j.thromres.2008.06.006. View

11.

Nomura S, Konishi A, Tsubokura Y, Azuma Y, Hotta M, Yoshimura H . Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2019; 57:101247. DOI: 10.1016/j.trim.2019.101247. View

12.

Yamanaka Y, Sawai Y, Nomura S . Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis. Int J Gen Med. 2020; 12:491-497. PMC: 6997194. DOI: 10.2147/IJGM.S236166. View

13.

Gao B, Wang S, Li J, Han N, Ge H, Zhang G . HMGB1, angel or devil, in ischemic stroke. Brain Behav. 2023; 13(5):e2987. PMC: 10176004. DOI: 10.1002/brb3.2987. View

14.

Aliotta A, Calderara D, Zermatten M, Marchetti M, Alberio L . Thrombocytopathies: Not Just Aggregation Defects-The Clinical Relevance of Procoagulant Platelets. J Clin Med. 2021; 10(5). PMC: 7956450. DOI: 10.3390/jcm10050894. View

15.

Agbani E, Poole A . Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis. Blood. 2017; 130(20):2171-2179. DOI: 10.1182/blood-2017-05-787259. View

16.

Piccin A, Murphy W, Smith O . Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2006; 21(3):157-71. DOI: 10.1016/j.blre.2006.09.001. View

17.

Dale G . Procoagulant Platelets: Further Details but Many More Questions. Arterioscler Thromb Vasc Biol. 2017; 37(9):1596-1597. DOI: 10.1161/ATVBAHA.117.309847. View

18.

Kornblit B, Masmas T, Petersen S, Madsen H, Heilmann C, Schejbel L . Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 16(2):239-52. DOI: 10.1016/j.bbmt.2009.10.002. View

19.

Tohidi-Esfahani I, Lee C, Liang H, Chen V . Procoagulant platelets: Laboratory detection and clinical significance. Int J Lab Hematol. 2020; 42 Suppl 1:59-67. DOI: 10.1111/ijlh.13197. View

20.

Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J . Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest. 2015; 125(12):4638-54. PMC: 4665785. DOI: 10.1172/JCI81660. View